Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs

• Verfasst von: Behrens, Frank [VerfasserIn]
• Verfasst von: Lorenz, Hanns-Martin [VerfasserIn]
• Titel: Simultaneous response in several domains in patients with psoriatic disease treated with Etanercept as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs
• Verf.angabe: Frank Behrens, Lothar Meier, Jörg C. Prinz, Jürgen Jobst, Ralph Lippe, Peter-Andreas Löschmann and Hanns-Martin Lorenz
• E-Jahr: 2018
• Jahr: June 1, 2018
• Umfang: 9 S.
• Fussnoten: Gesehen am 10.03.2020
• Titel Quelle: Enthalten in: The journal of rheumatology
• Ort Quelle: Toronto, Ont., 2001
• Jahr Quelle: 2018
• Band/Heft Quelle: 45(2018), 6, Seite 802-810
• ISSN Quelle: 1499-2752
• DOI: doi:10.3899/jrheum.170932
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: DERMATOLOGY
• Sach-SW: ETANERCEPT
• Sach-SW: MUSCULOSKELETAL DISEASE
• Sach-SW: PSORIATIC ARTHRITIS
• Sach-SW: QUALITY OF LIFE
• K10plus-PPN: 169199989X

Abstract

Objective. To evaluate patients with psoriatic arthritis (PsA) receiving etanercept (ETN) monotherapy or ETN plus conventional synthetic disease-modifying antirheumatic drugs (csDMARD) to determine the proportion achieving a clinically meaningful response in arthritis, psoriasis, and quality of life simultaneously. - Methods. A prospective, multicenter, 52-week observational study in patients with active PsA evaluated treatment with ETN in clinical practice (ClinicalTrials.gov: NCT00293722). This analysis assessed simultaneous achievement of 3 treatment targets: low disease activity (LDA) based on 28-joint count Disease Activity Score (DAS28); body surface area (BSA) involvement ≤ 3%; and a score > 45 on the Medical Outcomes Study Short Form-12 (SF-12) physical component summary. - Results. Of 579 patients, 380 received ETN monotherapy and 199 received combination ETN plus csDMARD. At 52 weeks, data for all 3 disease domains were available for 251 patients receiving monotherapy and 151 receiving combination therapy. In the monotherapy and combination therapy groups, 61 (24.3%) and 37 (24.5%) patients, respectively, achieved all 3 treatment targets simultaneously. A significantly greater proportion of patients receiving monotherapy versus combination therapy achieved SF-12 > 45 (43.0% vs 31.8%; p < 0.05) and DAS28 LDA (72.5% vs 62.3%; p < 0.05). Conversely, BSA ≤ 3% was reached by a significantly greater proportion receiving combination therapy (75.5% vs 56.6%; p < 0.001). However, baseline BSA involvement was higher for the monotherapy group. - Conclusion. While nearly half the patients achieved arthritis and psoriasis treatment targets simultaneously and one-fourth reached all 3 treatment targets, combining ETN and csDMARD did not substantially improve clinical response compared with ETN monotherapy in this real-world PsA patient population.